FC Grand Capital

FC Grand Capital is a strategic investment and holding subsidiary of Grand Pharmaceutical Group Limited, a leading diversified pharmaceutical company based in China and Hong Kong. The entity primarily functions as a vehicle for international mergers, acquisitions, and strategic partnerships to expand the group's global footprint in high-growth therapeutic areas. Its portfolio includes significant interests in interventional oncology, most notably through the $1.4 billion acquisition of Sirtex Medical and its Yttrium-90 resin microspheres technology. FC Grand Capital plays a crucial role in the group's innovation-driven strategy, focusing on bringing advanced medical technologies and therapies to the Chinese and global markets. Through its parent, it manages a robust pipeline across oncology, cardiovascular disease, and ophthalmology.